Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7668197 | 0.89 | SLC6A3 (0.54) | SLC6A3SLC6A4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6629659 | 0.86 | CYP4F2 (0.49) | SLC6A3SLC6A4KDM4ECYP4F2CYP4A11 | |
| SCHEMBL6799548 | 0.85 | CFTR (0.50) | SLC6A3SLC6A4KDM4ECYP4F2CYP4A11 | |
| SCHEMBL23354126 | 0.84 | SLC6A3 (0.71) | SLC6A3SLC6A4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31676847 | 0.84 | SLC6A3 (0.71) | SLC6A3SLC6A4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31676876 | 0.83 | SLC6A3 (0.57) | SLC6A3SLC6A4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23354164 | 0.83 | SLC6A3 (0.57) | SLC6A3SLC6A4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7565130 | 0.82 | LTB4R2 (0.48) | KDM4ECYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL28949910 | 0.80 | KDM4E (0.56) | SLC6A3SLC6A4SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL7249446 | 0.80 | SLC6A3 (0.65) | SLC6A3SLC6A4NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1054865-A1 | FARNESYL TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999041235-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | SLC6A3 4263/4885SLC6A4 4654/4885NPC1 535/4885 |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | SLC6A3 4218/4885SLC6A4 4443/4885NPC1 74/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | SLC6A3 4445/4885SLC6A4 4620/4885NPC1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.